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 56 
Abstract 57 
 58 
Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by 59 
dysplasia, abnormal production and accumulation of monocytic cells and an elevated 60 
risk to transform into acute leukemia. Over the past two decades, our knowledge about 61 
the pathogenesis and molecular mechanisms in CMML has increased substantially. In 62 
parallel, better diagnostic criteria and therapeutic strategies have been developed. 63 
However, many questions remain regarding prognostication and optimal therapy. In 64 
addition, there is a need to define potential pre-phases of CMML and special CMML 65 
variants, and to separate these entities from each other and from conditions mimicking 66 
CMML. To address these unmet needs, an international consensus group met in a 67 
Working Conference in August 2018 and discussed open questions and issues around 68 
CMML, its variants, and pre-CMML conditions. The outcomes of this meeting are 69 
summarized herein and include diagnostic criteria and a proposed classification of pre-70 
CMML conditions as well as refined minimal diagnostic criteria for classical CMML 71 
and special CMML variants, including oligomonocytic CMML and CMML associated 72 
with systemic mastocytosis. Moreover, we propose diagnostic standards and tools to 73 
delineate between ´normal´, pre-CMML and CMML entities. These criteria and 74 
standards should facilitate diagnostic and prognostic evaluations in daily practice and 75 
clinical studies in applied hematology. 76 
 77 
78 
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 79 
Introduction 80 
 81 
Chronic myelomonocytic leukemia (CMML) is a myeloid stem cell disease 82 
characterized by an abnormal production and accumulation of monocytic cells, often 83 
in association with other signs of myeloproliferation, substantial dysplasia in one or 84 
more hematopoietic cell lineages, and an increased risk of transformation into 85 
secondary acute myeloid leukemia (sAML).1-5 As per definition, the Philadelphia 86 
chromosome (Ph) and the related BCR-ABL1 fusion gene are absent in CMML. Other 87 
disease-related drivers, such as the JAK2 mutation V617F or the KIT mutation D816V, 88 
may be detected and may indicate a special variant of CMML, such as CMML 89 
associated with systemic mastocytosis (SM-CMML).6-8 However, most somatic 90 
mutations identified in CMML patients, such as mutations in SRSF2, TET2, or RAS, 91 
are not disease-specific, but are also detected in myelodysplastic syndromes (MDS), 92 
myeloproliferative neoplasms (MPN), or AML.8-11 93 
For many years, CMML was listed as a separate variant amongst the MDS in the 94 
classification of the French-American-British (FAB) working group.2,12 However, in 95 
2001, the World Health Organization (WHO) reclassified CMML into a newly created 96 
MDS/MPN overlap group, defined by the presence of both, MDS-related and MPN-97 
related morphologic and clinical features.13 Depending on the leukocyte count, CMML 98 
can be divided into a ´dysplastic´ variant (leukocyte count ≤13x109/L) and a 99 
´proliferative´ variant (leukocyte count >13x109/L).2 In 2001 and 2008, the WHO also 100 
proposed a split into CMML-1 and CMML-2, based on the percentage of blast cells in 101 
the blood and BM.13,14 In the most recent update of the WHO 2016 classification, 102 
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CMML is again listed amongst the MDS/MPN overlap disorders.15,16 Based on the 103 
percentage of blasts, CMML is now divided into CMML-0, CMML-1, and CMML-104 
2.15-19 Moreover, contrasting the 2008 WHO classification, the diagnosis of CMML 105 
now requires both, an absolute monocytosis (≥1×109/L) and relative monocytosis 106 
(≥10% of leukocytes) in the peripheral blood (PB).15,16,18,19 In the 2008 and 2016 107 
update of the WHO classification, CMML can only be diagnosed per definition when 108 
rearrangements in PDGFRA, PDGFRB or FGFR1 genes have been excluded, and in 109 
the 2016 update, the PCM1-JAK2 fusion gene was added as an excluding criterion.14-110 
16,19 These molecular aberrations are commonly found in eosinophilia-associated 111 
neoplasms such as chronic eosinophilic leukemia.20,21 However, CMML is also listed 112 
as an underlying variant in these molecular ´entities´ in the WHO classification 113 
system.20,21 114 
Over the past two decades, our knowledge about molecular features and mechanisms 115 
in CMML has increased substantially.4-11,22-26 Moreover, new diagnostic criteria, 116 
prognostic markers, and therapeutic concepts have been developed.26-29 Nevertheless, a 117 
number of questions remain concerning basic diagnostic standards, prognostication, 118 
optimal management and therapeutic options. Furthermore, there is a need to define 119 
clinically relevant pre-phases of CMML and distinct CMML variants by clinical 120 
variables, histomorphologic features, flow cytometric phenotypes, molecular markers 121 
and cytogenetic findings. It is also important to separate CMML and pre-CMML 122 
conditions from diverse mimickers. To address these unmet needs, an international 123 
consensus group discussed open questions and issues around CMML, its variants and 124 
pre-CMML entities in a Working Conference held in August 2018. The outcomes of 125 
this meeting are summarized in this article and include proposed diagnostic criteria 126 
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and a classification of pre-CMML conditions as well as updated minimal diagnostic 127 
criteria for CMML and its variants. In addition, diagnostic standards and diagnostic 128 
algorithms are proposed. Details concerning the conference format, pre- and post-129 
conference discussion and consensus-finding are described in the supplement. 130 
 131 
Definition of CMML and Minimal Diagnostic Criteria 132 
 133 
The diagnostic criteria of CMML, as defined by the WHO15,16 are depicted in 134 
Supplementary Table S1. Our faculty is of the opinion that these criteria are valid in 135 
general for the classical form of CMML, but need adjustments for special variants of 136 
CMML. Based on consensus discussion, the following concept is proposed:  137 
The classical form of CMML is defined by the following pre-requisite criteria: 1) 138 
persistent (at least 3 months) absolute PB monocytosis (≥1×109/L) and relative 139 
monocytosis (≥10% of PB leukocytes), 2) exclusion of BCR-ABL1+ leukemia, 140 
classical MPN and all other hematologic neoplasms that may serve as primary source 141 
of monocytosis, and 3) a blast cell count of 0-19% in PB and/or BM smears and 142 
exclusion of all (other) histopathologic, morphologic, phenotypic, molecular and 143 
cytogenetic signs that qualify as evidence of AML. In addition, morphologic and/or 144 
histopathologic evidence for diagnostic dysplasia in one or more of the 3 major BM 145 
cell lineages (≥10% of megakaryocytes and/or erythroid precursor cells and/or 146 
neutrophilic cells) has to be present. If dysplasia is absent or not diagnostic (<10%), 147 
the presence of cytogenetic or molecular lesions (mutations) typically found in CMML 148 
and/or the presence of CMML-related flow cytometry abnormalities may be employed 149 
as co-criteria and may lead to the diagnosis of CMML, provided that the pre-requisite 150 
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criteria listed above are fulfilled. Pre-requisite criteria and co-criteria of the classical 151 
form of CMML are depicted in Table 1. 152 
The exclusion of various reactive states producing monocytosis (and sometimes even 153 
dysplasia) was also discussed and regarded as being of great importance. However, 154 
these mimickers cannot ´a priori´ exclude the presence of a concomitant CMML, but 155 
may indeed occur in CMML patients in the context of certain infections. Furthermore, 156 
most of these mimickers do not produce persistent monocytosis. Proof of clonality by 157 
molecular and cytogenetic studies, and other disease-specific parameters, together with 158 
global and specific laboratory (e.g., microbial screen) tests should easily lead to the 159 
conclusion that the patient is suffering from reactive monocytosis but not from (or also 160 
from) CMML. 161 
The ´a priori´ exclusion of AML as criterion should apply to both, the classical and the 162 
special variants of CMML, whereas the ´a priori´ exclusion of other indolent 163 
hematopoietic neoplasms should only apply to the classical variant of CMML and 164 
oligomonocytic CMML but not to other special CMML variants. This is because 165 
several previous and more recent studies have shown that CMML may be 166 
accompanied by (or may accompany) other myeloid or lymphoid neoplasms, such as 167 
systemic mastocytosis. In several of these patients, the CMML clone is dominant and 168 
the additional sub-clone is smaller in size and usually not relevant clinically, even if 169 
these smaller clones express certain driver mutations, such as KIT D816V or a 170 
rearranged PDGFRA or PDGFRB. Rarely, a Ph+ CML may develop as additional 171 
small-sized (sub)clone in a patient with CMML. Our faculty is of the opinion that the 172 
presence of additional (chronic) myeloid, mast cell, or lymphoid neoplasms does not 173 
exclude a diagnosis of CMML, provided that diagnostic WHO criteria for CMML are 174 
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fulfilled. Moreover, these concomitant neoplasms should not exclude a diagnosis of 175 
CMML even when the driver of the concomitant disease (e.g., KIT D816V) is 176 
detectable in CMML monocytes. Thus, whereas the occurrence of AML is always 177 
regarded as transformation of CMML, the occurrence of indolent myeloid, mast cell, 178 
or lymphoid neoplasms should be regarded as concomitant disorders. Co-existing 179 
myeloid neoplasms and CMML may be derived from the same original founder-clone. 180 
There are also patients in whom a certain driver of another BM neoplasm is present, 181 
such as a mutated JAK2, PDGFRA/B, or FGFR1, but only the diagnostic criteria for 182 
CMML (not that of the other BM neoplasm) are fulfilled. Our faculty concludes that 183 
these cases should also be regarded and diagnosed as special variants of CMML. This 184 
strategy is in line with the current WHO classification. In fact, whereas the primary 185 
molecular diagnosis is often based on a mutated form of JAK2, PDGFRA/B or other 186 
classical driver, the underlying or additional diagnosis may well be CMML.20,21  187 
 188 
Grading of CMML 189 
 190 
The grading system of CMML proposed by the WHO is regarded as the standard in 191 
clinical hematology. Our faculty recommends the use of this grading system as initial 192 
prognostic tool in classical CMML. In fact, classical CMML should be split into 193 
CMML-0, CMML-1 and CMML-2 based on the blast cell count (Supplementary Table 194 
S2).15-19 In addition, CMML can be divided into a dysplastic variant and a proliferative 195 
variant based on leukocyte counts (threshold: 13x109/L) (Supplementary Table S2). 196 
The resulting grading system defines 6 distinct CMML variants with variable clinical 197 
outcome.17 However, grading may sometimes be challenging. For example, blast cell 198 
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counts obtained from BM smears may differ from those obtained in the PB so that the 199 
grade is in question. Our faculty recommends that in patients in whom results from 200 
BM and PB smears would not fit into one distinct grade of CMML (e.g., BM blasts 201 
4% and PB blasts 6%) grading should be based on the higher blast cell percentage 202 
(Supplementary Table S2). It is worth noting that initial prognostication by grading 203 
does not include all essential prognostic parameters. Therefore, we recommend that in 204 
each case, deeper (full) prognostication should follow using multiparametric scoring 205 
systems (see later). It should be noted, however, that grading of CMML has only been 206 
validated in the classical form of CMML, but not in special CMML variants. 207 
Therefore, although grading is recommended also for special CMML entities, it is not 208 
regarded standard and the result must be interpreted with caution in these patients.  209 
 210 
Special variants of CMML - Overview 211 
 212 
As mentioned before, the classical form of CMML meets all pre-requisite criteria, and 213 
no signs (including molecular features) of an additional, concomitant BM neoplasm 214 
are detected. The special variants of CMML form a heterogeneous group of neoplasms 215 
comprising distinct clinical and biological entities. In one group of patients, the 216 
relative monocyte count (≥10%) is fulfilled without resulting in an absolute count 217 
equal or higher than 1×109/L, precluding the diagnosis of ´classical CMML´. Most of 218 
these patients are diagnosed as MDS or MPN/MDS-U by WHO criteria. In another 219 
group of patients, a molecular signature suggestive of a different type of myeloid 220 
neoplasm is detected but only the criteria for CMML (not that for the other neoplasm) 221 
are met. Such an example is CMML with JAK2 V617F (without definitive evidence of 222 
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a concomitant MPN). In a third group, CMML co-exists with another BM neoplasm, 223 
such as MPN or mastocytosis. In these patients, additional blood count abnormalities 224 
(e.g., eosinophilia), an elevated serum tryptase level and/or BM fibrosis, may be 225 
detected.  226 
All variants of CMML (classical and special) can occur as a) primary CMML or as b) 227 
secondary CMML following a ´mutagenic´ event, such as chemotherapy (therapy-228 
related CMML). In addition, our faculty is of the opinion, that the term secondary 229 
CMML may also be appropriate for those patients who develop CMML (months or 230 
years) after another indolent myeloid neoplasm, such as a MDS or systemic (indolent 231 
or aggressive) mastocytosis, had been diagnosed. In the following paragraphs, the 232 
clinical features and diagnostic criteria of special (atypical) variants of CMML are 233 
proposed and discussed. An overview of the special variants of CMML is provided in 234 
Table 2. 235 
 236 
Oligomonocytic CMML 237 
 238 
Over the past few years, more and more cases of cytopenic patients exhibiting relative 239 
monocytosis (≥10%) and moderately increased absolute blood monocytes not reaching 240 
the required threshold to diagnose classical CMML (1.0x109/L) have been described. 241 
These cases have recently been referred to as oligomonocytic CMML.30 According to 242 
the WHO classification most of these patients would be classified as MDS (with 243 
monocytosis) or perhaps MPN/MDS-U. However, most of these patients exhibit 244 
typical features of CMML, including a typical morphology of PB and BM cells, 245 
splenomegaly, and CMML-related molecular features (e.g. mutations in TET2 and 246 
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SRSF2).30-32 Some of these patient have prominent BM monocytosis without 247 
diagnostic peripheral blood monocytosis at diagnosis.32  248 
Whereas several of these cases remain stable without progression, the majority will 249 
develop ´overt´ CMML or eventually, secondary AML during follow-up. Therefore, 250 
oligomonocytic CMML may also be regarded as a potential pre-phase of classical 251 
CMML. Our faculty is of the opinion, that the term oligomonocytic CMML should be 252 
used in clinical practice. Diagnostic pre-requisite criteria for oligomonocytic CMML 253 
are: 1) persistent (at least 3 months lasting) absolute peripheral monocytosis of 0.5-254 
0.9×109/L and relative blood monocytosis (≥10% of blood leukocytes) 2) exclusion of 255 
BCR-ABL1+ leukemia, classical MPN and all other myeloid neoplasms that can 256 
explain monocytosis, and 3) a blast cell count of 0-19% in PB and/or BM smears and 257 
exclusion of all histopathologic, morphologic, phenotypic, molecular and cytogenetic 258 
signs that count as proof of AML. Diagnostic dysplasia in one or more of the 3 major 259 
BM lineages (≥10%) must also be documented. If dysplasia is lacking or ´sub-260 
diagnostic´ (<10%), the presence of cytogenetic or molecular lesions (mutations) 261 
typically found in CMML and/or the presence of CMML-related flow cytometry 262 
abnormalities, may also lead to the conclusion the patient has oligomonocytic CMML 263 
provided that the other diagnostic criteria described above are fulfilled and all other 264 
myeloid neoplasms have been excluded. The proposed criteria for oligomonocytic 265 
CMML are depicted in Table 3. Patients with oligomonocytic CMML should be 266 
managed and followed clinically in the same way as patients with classical CMML. 267 
 268 
CMML associated with KIT D816V+ systemic mastocytosis (SM) 269 
 270 
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According to WHO criteria, SM can be divided into i) indolent SM (ISM) where life 271 
expectancy is normal, ii) smoldering SM (SSM) where signs of BM dysplasia, 272 
myeloproliferation and/or splenomegaly are found but survival and prognosis are still 273 
favorable, and iii) advanced SM defined by poor prognosis.33-36 Advanced SM is 274 
further divided into aggressive SM (ASM), SM with an associated hematologic 275 
neoplasm (SM-AHN) and mast cell leukemia (MCL).33-36 The most frequent AHN 276 
detected in patients with SM-AHN is CMML.6-8,36 In these patients the SM component 277 
of the diseases may present as ISM, ASM or, rarely, as MCL. Our faculty concludes 278 
that diagnostic WHO criteria for SM and diagnostic criteria for classical CMML 279 
(except exclusion of SM) have to be fulfilled to diagnose SM-CMML. 280 
Patients with SM may present with monocytosis resembling oligomonocytic CMML. 281 
However, the clinical features of SSM and advanced SM overlap largely with those 282 
found in patients with oligomonocytic CMML. Especially in SSM, myelo-283 
proliferation, dysplasia and splenomegaly are diagnostic criteria.33-35 Therefore our 284 
faculty is of the opinion that such patients should be classified as ISM, SSM or ASM 285 
with monocytosis rather than SM with oligomonocytic CMML. 286 
In patients with CMML, a concomitant SM is often overlooked especially when the 287 
disease does not present with cutaneous lesions. In other patients, CMML is diagnosed 288 
long before SM is detected by chance or after the KIT D816V is identified: even 289 
though it is tempting to call these conditions CMML-SM, our faculty agreed that the 290 
classical terminology should be SM-CMML which is also in line with the WHO 291 
classification34,35 and that the subtype of SM and of CMML should be defined in the 292 
final diagnosis (e.g., ISM-CMML-1 or ASM-CMML-2) with recognition that in the 293 
SM-context, CMML is always a secondary neoplasm.6,36 Furthermore our faculty is of 294 
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the opinion that it is standard to examine BM and blood leukocytes for the presence of 295 
KIT D816V in all patients with (suspected) CMML. In almost all patients with SM-296 
CMML, neoplastic monocytes display KIT D816V.7 In these monocytes, mutated KIT 297 
is not expressed on the cell surface but acts as a cytoplasmic driver lesion. In line with 298 
this hypothesis drugs targeting KIT D816V can sometimes induce a major decrease in 299 
monocyte counts in patients with ASM-CMML.37 300 
Therapy of SM-CMML should be based on a bi-directional strategy: in fact the SM 301 
component of the disease should be treated as if no CMML was diagnosed and CMML 302 
should be treated as if no SM was found, with recognition of drug-drug interactions 303 
and the possibility of drug-induced anaphylaxis.33-35 In many cases (ISM-CMML) the 304 
SM component of the disease is only treated symptomatically.33-35 305 
 306 
CMML associated with mutated JAK2, rearranged PDGFRA/B or other drivers  307 
 308 
Patients with CMML may present with the JAK2 mutation V617F, a rearranged 309 
PDGFRA or PDGFRB, often in the context of hypereosinophilia, or other drivers 310 
related to distinct hematopoietic neoplasms as defined by the WHO.5,9-11,38-43  311 
a) CMML with rearranged PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2: 312 
In these patients, persistent substantial monocytosis (≥1.0x109/L) is detected and all 313 
other consensus criteria of classical CMML (see previous paragraphs) are also met, 314 
except the following specific exclusion criteria: CMML to be excluded in the presence 315 
of a well characterized diagnosis of myeloid/lymphoid neoplasm with rearranged 316 
PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2 (Table 2). Except for neglecting the 317 
above mentioned criteria, our proposal is otherwise fully in agreement with all of the 318 
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other tenets postulated by the WHO classification.20,21  In relation to neoplasm with 319 
rearranged PDGFRA/B, FGFR1 or PCM1-JAK2, their definition of ´myeloid/lymphoid 320 
neoplasms´ is too generic and there is a clinical need to know whether the underlying 321 
myeloid neoplasm is an aggressive disease, like AML, or a chronic neoplasm such as 322 
CMML or chronic eosinophilic leukemia (CEL). Our faculty is of the opinion that 323 
(unlike in previous times) the presence of one criteria-confirmed myeloid neoplasm 324 
should not ´a priori´ exclude the presence of another (second concomitant) myeloid or 325 
lymphoid neoplasm. Hence, when CMML is encountered in the context of another 326 
molecularly defined myeloid/lymphoid neoplasm (as a final diagnosis), it should be 327 
delineated as a specific subtype of the myeloid/lymphoid neoplasm with eosinophilia 328 
along with the specific associated gene rearrangement (PDGFRA/B or FGFR1 or 329 
PCM1-JAK2). 330 
a) CMML with JAK2 V617F: 331 
In these patients the situation is different. First, JAK2 V617F itself may be considered 332 
as a criterion of myeloproliferation in MDS/MPN, e.g. in cases with MDS/MPN with 333 
ring sideroblasts and thrombocytosis. In the CMML-context, the JAK2 mutation is also 334 
typically associated with other signs of myeloproliferation (including BM fibrosis) and 335 
with the ´myeloproliferative variant´ of CMML.39,42,43 Therefore, our faculty concludes 336 
that JAK2 V617F should also count as a molecular co-criterion of MDS/MPN and thus 337 
for CMML. Second, the presence of a JAK2-mutated MPN does not exclude the 338 
presence of a concomitant CMML if diagnostic criteria for both neoplasms are 339 
fulfilled. If this is not the case because the size of the MPN-like clone carrying JAK2 340 
V617F is too small and/or other MPN features are clearly missing, the final diagnosis 341 
will be CMML with JAK2 V617F. On the other hand, in patients in whom the JAK2 342 
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allelic burden is high and clinical and laboratory features argue for an overt MPN 343 
rather than CMML (e.g., polycythemia and/or BM fibrosis without dysplasia and 344 
without molecular or flow cytometry-based signs of CMML) the final diagnosis will 345 
be JAK2 V617F+ MPN with monocytosis.43 In a third group of patients, diagnostic 346 
criteria for both, a distinct MPN and CMML, are fulfilled and the mutation status 347 
confirms the presence of an overt JAK2-mutated MPN (usually with high allelic 348 
burden). These patients are suffering from both, MPN and CMML or from a gray zone 349 
disease displaying hybrid features between MPN and CMML.44,45 Our faculty 350 
concludes that it is therefore important to measure the JAK2 V617F allele burden in all 351 
patients with CMML.39,42,43 Other drivers, such as BCR-ABL1, are rarely found in 352 
patients with CMML. However, although in classical CMML, the presence of BCR-353 
ABL1 must be excluded, it may be detected in rare patients suggesting the existence of 354 
a special variant of CMML (defined by a co-existing CML). In some of these cases, 355 
the CML clone may be small-sized. In other patients, however, the CML may even 356 
mask CMML at initial diagnosis.46 357 
Management and therapy of patients with special variants of CMML depends on the 358 
subtype of the disease and the molecular driver involved, like FIP1L1/PDGFRA, other 359 
gene abnormalities involving PDGFRA or PDGFRB, KIT D816V or JAK2 V617F. 360 
Therefore, it is of crucial importance to screen (ask) for all these drivers in all patients 361 
with CMML. The type of therapy to consider in these patients depends on clinical 362 
features, the histopathological diagnosis, the size of the mutated clone(s) and the type 363 
of driver. The latter is of considerable importance since novel treatments directed 364 
against these drivers, are often extremely effective.47-50 For example, imatinib can 365 
induce long-lasting molecular and hematologic complete remissions (CR) in patients 366 
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with FIP1L1/PDGFRA-rearranged myeloid neoplasms with features of CMML or 367 
MPN.47-49 Even in patients who develop CMML and secondary AML in the context of 368 
FIP1L1/PDGFRA, the disease may respond to imatinib.50 Therefore, it is important to 369 
diagnose all patients based on molecular markers and to define the major drivers and 370 
therapeutic targets expressed by malignant cells in order to provide optimal 371 
management and therapy. 372 
 373 
CMML associated with lymphoid neoplasms 374 
 375 
In a small group of patients with CMML, a co-existing lymphoproliferative neoplasm 376 
is diagnosed, such as a lymphocytic leukemia, non-Hodgkin lymphoma or multiple 377 
myeloma.51-60  In most patients, the lymphoid neoplasm is detected first, and CMML is 378 
considered to develop as treatment-induced, secondary, leukemia.51,57 In other patients, 379 
CMML is first diagnosed, and later, a lymphoid neoplasm is detected during follow-380 
up.52-56 It is worth noting that in patients with CMML, polyclonal 381 
hypergammaglobulinemia is often recorded which must be distinguished from the 382 
monoclonal gammopathy of concomitant myeloma, monoclonal gammopathies of 383 
undetermined significance (MGUS) and both low-count and high-count monoclonal B 384 
lymphocytosis (MBL) which represent pre-malignant conditions. 385 
Management and treatment of lymphoid neoplasms presenting with concomitant 386 
(secondary) CMML is a clinical challenge. In non-transplantable cases, both diseases 387 
require separate treatment plans. Because of the high-risk regarding transformation to 388 
AML, allogeneic hematopoietic stem cell transplantation (allo-HSCT) should be 389 
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considered in young and fit patients, especially when it can be expected that the 390 
lymphoid neoplasm will also be eradicated by this approach.  391 
 392 
Treatment-related CMML (t-CMML) and other secondary forms of CMML  393 
 394 
Our faculty concludes that both the classical form of CMML and the special variants 395 
of CMML should be divided into primary (de novo) CMML and secondary CMML 396 
(sCMML). The latter group includes patients who i) received chemotherapy and/or 397 
radiation therapy in the past (therapy-related CMML) or ii) have a history of a 398 
preceding MDS, MPN or another indolent myeloid or mast cell neoplasm prior to the 399 
CMML diagnosis.51,57,58,61-64 Recent data suggest that patients with therapy-related 400 
sCMML (t-CMML) may have shorter overall survival compared to patients with 401 
primary (de novo) CMML.65 Although progression-free survival may not be different 402 
in these patients compared to de novo CMML, some of these patients progress rapidly 403 
to secondary AML. It is also worth noting that patients with t-CMML have a higher 404 
frequency of karyotypic abnormalities compared to de novo CMML.66 Eligible 405 
patients in this group should be offered allo-HSCT. 406 
  407 
Potential Pre-Phases of CMML 408 
 409 
During the past few years evidence has accumulated suggesting that hematopoietic 410 
neoplasms, including MDS, MPN and MDS/MPN, develop in a step-wise manner. In 411 
the earliest phases of clonal development, patients present without overt signs or 412 
symptoms of a hematopoietic neoplasm but their leukocytes carry one or more somatic 413 
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mutations, usually (early, passenger-type) mutations otherwise also found in overt 414 
myeloid neoplasms (for example TET2 mutations).67-70 In the context of MDS and 415 
other myeloid neoplasms, these cases have been referred to as clonal hematopoiesis of 416 
indeterminate potential (CHIP), or, when accompanied by cytopenia, as clonal 417 
cytopenia of unknown significance (CCUS).69-73 Since these mutations are frequently 418 
detected in older individuals, the condition is also called age-related clonal 419 
hematopoiesis (ARCH).70,73 In a few healthy individuals, bona fide oncogeneic drivers 420 
(such as BCR-ABL1) are detected in a small subset of leukocytes. Because of the 421 
oncogenic potential of these drivers, these conditions are termed clonal hematopoiesis 422 
with oncogenic potential (CHOP).71,73 CHIP, CCUS and CHOP may also be the 423 
earliest clonal conditions preceding CMML. For these cases, the definitions recently 424 
proposed for CHIP, CCUS and CHOP should apply.69,71,73 425 
Apart from somatic mutations, other factors, such as epigenetic modifications, chronic 426 
inflammation or ageing-related processes, may also trigger the selection and expansion 427 
of pre-malignant neoplastic clones in myeloid neoplasms including CMML.74-76 Some 428 
of these conditions may present with persistent monocytosis without signs of an overt 429 
myeloid neoplasm and may represent pre-phases of overt CMML. In other patients, 430 
however, no or another hematopoietic neoplasm develops during follow-up. Therefore, 431 
our faculty concluded that this pre-phase should be termed idiopathic monocytosis of 432 
unknown significance (IMUS), provided that the following criteria are met: i) 433 
persistent (at least 3 months) relative (≥10%) and absolute (>0.5x109/L) monocytosis, 434 
ii) no diagnostic dysplasia and no signs of myeloproliferation, iii) no signs and criteria 435 
of a myeloid or other hematopoietic neoplasm fulfilled, iv) no flow cytometric 436 
abnormalities or somatic mutations related to a myeloid, mast cell or lymphoid 437 
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neoplasm detected in leukocytes, and v) no reactive condition that would explain 438 
reactive monocytosis is detected (Table 4 and Supplementary Table S3). If in such 439 
patient CHIP-like mutations are found, but no hematopoietic neoplasm can be 440 
diagnosed using WHO criteria, the final diagnosis changes to clonal monocytosis of 441 
unknown significance (CMUS) (Supplementary Table S3). It is also worth noting that 442 
idiopathic cytopenias of unknown significance (ICUS) can precede CMML.64,77-79 443 
Especially in patients with idiopathic thrombocytopenia of unknown significance 444 
(ICUS-T), a CMML may be detected upon deeper investigations or during follow-445 
up.77-79 Finally, as mentioned before, oligomonocytic CMML, although proposed as a 446 
special variant of CMML, must also be regarded as a potential pre-phase of classical 447 
CMML. In this regard it is important to note that these patients should have a regular 448 
follow-up with repeated investigations of all disease-related parameters. A summary of 449 
non-clonal and clonal conditions potentially preceding CMML is shown in Table 4. 450 
With regard to criteria delineating non-clonal pre-diagnostic conditions, like ICUS 451 
from the clonal conditions described above (CHIP, CCUS, CHOP), we refer to the 452 
pertinent literature.69,71,73 453 
 454 
PB and BM Smears: Proposed Standards and Recommendations 455 
 456 
As in other myeloid neoplasms, a thorough examination of appropriately prepared and 457 
stained BM and PB smears is a crucial diagnostic approach in suspected CMML. It is 458 
standard to examine and count at least 100 leukocytes in the PB film and 200-500 459 
nucleated cells in well-prepared thin BM films. BM cellularity, the erythroid-to-460 
myeloid (E:M) ratio, and the percentage of blast cells (including monoblasts and 461 
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promonocytes), monocytes, mast cells, and other myeloid cells must be recorded 462 
(reported) in each case. Like in patients with MDS, at least 10% of cells in one of the 463 
major BM lineages (erythroid or/and neutrophil or/and megakaryocyte) need to be 464 
dysplastic to meet the dysplasia criterion of CMML.13-18 It is also standard to study 465 
well-prepared and appropriately stained PB smears in CMML and to report the 466 
percentage of circulating monocytes, including normal (mature) and abnormal 467 
(immature) monocytes, blast cells, other immature myeloid cells, dysplastic 468 
(hypogranulated) neutrophils and other cell types in the PB. Overall, the same 469 
standards and recommendations that count for the evaluation of MDS by morphology 470 
(BM and PB stains)12,80-83 also apply in cases with (suspected) CMML.13-18 An 471 
important point is the classification of blast cells and monocytic cells in CMML (Table 472 
5).16,84 Blast cell types detectable in CMML include myeloblasts, monoblasts and also 473 
promonocytes (even if not named blast cells) (Table 5). Monocytes should be 474 
classified as normal (mature) or abnormal (immature).16,84 The morphologic criteria 475 
used to delineate between these cell types are depicted in Table 5. Together with 476 
morphology, cytochemical staining for non-specific esterase can also assist in the 477 
morphologic delineation between monocytes, monoblasts and promononcytes.16 An 478 
important aspect is that in many patients, megakaryocyte dysplasia is better 479 
documented and quantified in BM histology sections than in BM smears. Therefore, 480 
megakaryocyte dysplasia should only be recorded in BM smears when a sufficient 481 
number of these cells can be detected. Finally, the morphology of mast cells, when 482 
detected, should always be reported using established criteria and standards.85 483 
 484 
BM Histology and Immunohistochemistry (IHC) in CMML 485 
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 486 
A thorough investigation of an appropriately processed and stained BM biopsy section 487 
by histology and IHC is standard in all cases with known or suspected CMML or a 488 
suspected pre-CMML condition.14-16,30,86 Notably, BM histology and IHC are an 489 
essential approach to confirm the diagnosis of CMML and to exclude AML and other 490 
CMML-mimickers. Moreover, BM histology and IHC may provide important 491 
additional information, including BM fibrosis, focal accumulations of blast cells, 492 
increased angiogenesis, atypical (dysplastic) megakaryocytes, a hypocellular BM or 493 
concomitant mastocytosis (Supplementary Table S4).33-35,86 The evaluation and 494 
enumeration of CD14+ monocytes, CD34+ progenitor cells and CD117+/KIT+ cells 495 
(progenitors and mast cells) by IHC in BM biopsy sections represent an integral part of 496 
the diagnostic assessment. This approach can also prevent diagnostic errors. For 497 
example, when the smear is of suboptimal quality, a preliminary diagnosis of CMML 498 
may change to AML based on BM histology and CD34 IHC.  499 
BM biopsy specimens are usually taken from the iliac crest and should be of adequate 500 
length (≥2 cm). The specimen should be fixed in neutral formalin (or alternative 501 
standard fixation), decalcified in EDTA (for at least 8 hours) or by alternative standard 502 
decalcification, and embedded in paraffin-wax. Ideally 2-3 µm-thin sections should be 503 
prepared. Routine stains include hematoxylin-eosin, Giemsa, Prussian blue, AS-D 504 
chloroacetate esterase (CAE), Toluidine Blue and silver impregnation (Gömöri´s 505 
stain). BM cellularity should be measured and reported according to published 506 
standards.87,88 For routine purposes, the pathologist should determine the cellularity as 507 
´normocellular´, ´hypocellular´, or ´hypercellular´, based on an age-adapted estimate.89 508 
The presence of variable degrees of BM fibrosis (usually mild to moderate) has been 509 
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reported in CMML cases with several recent studies attempting to determine its 510 
prognostic value.42,90,91 Indeed, although the data are not yet conclusive, the presence 511 
of marrow fibrosis in CMML seems to be of prognostic importance.42,90,91 512 
The application of IHC markers is recommended in all patients with (suspected) 513 
CMML. The minimal IHC-panel includes CD14 (monocytes), CD34 (progenitors), 514 
CD117/KIT (progenitors and mast cells), tryptase (mast cells), and a megakaryocyte 515 
marker (CD41, CD42 or CD61) (Supplementary Table S5).86,92,93 In unclear cases or 516 
when a co-existing (second) BM neoplasm is suspected, additional lineage-specific 517 
antibodies such as CD3, CD20, or CD25 (suspected mastocytosis) should be applied 518 
(Supplementary Table S4). When employing CD34 as a progenitor-related IHC 519 
marker, it is important to know that endothelial cells also express this antigen. Another 520 
important point is that blasts may sometimes be CD34-negative. In such cases, 521 
KIT/CD117 is applied as alternative marker (Supplementary Table S4). For the 522 
detection of monocytic cells, CD14 is a preferred IHC antigen.71,86 Tryptase and 523 
CD117 are useful IHC markers to detect and quantify mast cells.92,93 When spindle-524 
shaped mast cells form compact clusters in the BM and express CD25, these cells 525 
usually also display KIT D816V – in these cases the final diagnosis is always SM-526 
CMML.93 In other cases, the pathologist will ask for JAK2 V617F, based on an 527 
abnormal morphology and distribution of megakaryocytes. Like in MDS, 528 
megakaryocytes may also express CD34 in patients with CMML. 529 
 530 
Karyotyping in CMML: Current Recommendations and Standards 531 
 532 
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Clonal cytogenetic abnormalities are detected in 20-30% of all patients with CMML. 533 
The most frequently identified aberrations are trisomy 8, abnormalities of chromosome 534 
7 (especially monosomy 7 and deletion of 7q), and loss of the Y chromosome (‐Y) 535 
(Supplementary Table 6).94-97 Compared to MDS, isolated del(5q) and complex 536 
abnormal karyotypes are rarely detected in CMML. Our faculty is of the opinion that 537 
conventional karyotyping of BM cells should be performed in all patients with known 538 
or suspected CMML or a suspected pre-CMML condition. At least 20 metaphases 539 
should be examined.98 In the case of a clear-cut result, even 10-20 metaphases may be 540 
sufficient to define the karyogram. Reporting of karyotypes should be performed using 541 
ISCN guidelines.99 A clone is defined by 2 or more metaphases showing the same gain 542 
or structural rearrangement (deletion, inversion, translocation) of chromosomal 543 
material or at least 3 metaphases showing a monosomy of the same chromosome.99 544 
Several of the cytogenetic anomalies in CMML may be difficult to detect by 545 
conventional karyotyping. Therefore, we are of the opinion that fluorescence in situ-546 
hybridization (FISH) should be performed in all patients with (suspected) CMML, at 547 
least in those where no karyotype anomaly was detected by conventional karyotyping. 548 
The FISH probes should cover all relevant regions, including 5q31, cep7, 7q31, 20q, 549 
cep8, cepY and p53. Special consideration should be directed to kryptic deletions of 550 
TET2 (in 4q24), NF1 (17q11), and ETV6 (12p13) which can occur in up to 10% of 551 
CMML patients10 and is only detectable by interphase FISH (Supplementary Table 552 
S6). It is worth noting that NF1 deletions may occur during progression/katyotype 553 
evolution in CMML. The limitation of FISH is that is does not detect all karyotypic 554 
abnormalities. In some of the patients with CMML, clonal evolution is found. 555 
Subclones are defined by additional chromosomal defects (apart from the primary 556 
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chromosomal defect) in at least 2 cells (or 3 cells for monosomies) and absence of 557 
these additional chromosomal defects in the other clonal cells.99 A complex karyotype 558 
is defined by at least 3 chromosome defects in one clone.99 As in MDS, a complex 559 
karyotype in CMML is indicative of a poor prognosis. Overall, cytogenetic studies are 560 
of prognostic significance in CMML and have been used to optimize prognostic 561 
scoring systems.97,100-102 In some patients with CMML, clonal evolution is observed 562 
over time and may then also be an adverse prognostic sign. Therefore, we recommend 563 
that chromosome analyses are performed each time when a BM investigation is done 564 
in the follow-up in order to detect (or exclude) clonal evolution. 565 
 566 
Mutation Profiles in CMML: Current Standards and Limitations 567 
 568 
In the vast majority of patients with CMML, somatic mutations are detectable.8,11,103-569 
106 The clonal architecture, clone-sizes and clonal evolution patterns vary from patient 570 
to patient.106-108 In some cases, initially small-sized clones expand over time. 571 
Therefore, it is standard to apply next-generation sequencing (NGS) assays with 572 
sufficient sensitivity to identify bona fide somatic mutations associated with CMML. 573 
The most frequently detected somatic mutations in CMML are mutations in TET2 574 
(60%), SRSF2 (50%), and ASXL1 (40%) (Table 6).31,103-110 The presence of a SRSF2 575 
mutation, particularly in combination with mutated TET2, correlates strongly with a 576 
CMML phenotype.31,109,110 It is also worth noting that two of these mutations (TET2, 577 
ASXL1) are also known as CHIP/ARCH-related mutations. However, only mutated 578 
ASXL1 has been associated with a poor prognosis in CMML.104,109 An overview of 579 
somatic mutations recurrently detected in CMML is provided in Table 6. Somatic 580 
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mutations with independent prognostic impact include several RAS-pathway 581 
mutations as well as mutations in ASXL1, RUNX1 and SETBP1 (Table 6).31,103-111 RAS-582 
pathway mutations are triggering cell signaling and proliferation and have been 583 
associated with cytokine-independent growth of CMML progenitor cells, the 584 
proliferative variant of CMML, AML transformation and poor survival.10,22,23,112-116 585 
Other driver mutations involved in cell signaling, such as JAK2 V617F or KIT D816V, 586 
are also (in addition) major triggers of cellular differentiation (Supplementary Table 587 
S7). These drivers alone cannot induce transformation, but they may act together with 588 
other (e.g., ´RAS pathway´) mutations to cause disease progression. Whereas JAK2 589 
V617F is a strong indicator of MPN-like differentiation, the presence of KIT D816V is 590 
almost always associated with concomitant mast cell differentiation and mastocytosis 591 
(SM-CMML).6-8,32-36,39,42,43 The other mutations found in CMML act as modulators of 592 
epigenetic events and transcription (like ASXL1) or DNA methylation (like TET2), as 593 
regulators of the spliceosome machinery (like SRSF2), or as modulators of the DNA 594 
damage response, such as TP53 (Table 6). During progression of CMML to sAML and 595 
especially during therapy, the mutational landscape(s) and clonal architecture(s) may 596 
change.109-113 For example initially small-sized clones may expand and may be 597 
selected because of resistance-mediating molecular features. It is worth noting that 598 
several mutated gene products also serve as potential targets of therapy (Table 6). 599 
Our faculty recommends that NGS studies should be regarded as a standard approach 600 
in all patients with suspected or known CMML as well as in patients with idiopathic 601 
monocytosis of unknown significance (IMUS) and in those with persistent reactive 602 
monocytosis (in order to exclude an additional clonal component). When a CMML-603 
related mutation is found in an individual with IMUS or reactive monocytosis, the 604 
 25 
diagnosis may change to CMUS or oligomonocytic CMML (O-CMML) depending on 605 
additional findings. 606 
Our faculty also recommends that the NGS assay should have sufficient sensitivity (to 607 
detect 2-5% clonal cells) and should cover all relevant lesions depicted in Table 6. In 608 
the context of CHIP/ARCH, a cutoff of 2% variant allele frequency (VAF) is 609 
considered diagnostic69, whereas in the CMML context, we propose a 10% VAF as a 610 
diagnostic cut off and thus marker to count as a co-criterion of CMML when, for 611 
example, no diagnostic morphologic dysplasia could be documented (Tables 1 and 3) 612 
similar to the definition in MDS.71,73 Determining the VAF is also useful to document 613 
the clinical impact of certain driver lesions in special CMML variants (e.g., with 614 
JAK2 V617F or KIT D816V) and clone-expansion during follow-up. Therefore, our 615 
faculty recommends that molecular studies in CMML should report VAFs with 616 
sufficient precision and sufficient sensitivity – in the same way as in MDS.71,73 617 
Finally, our faculty recommends that molecular markers should increasingly be used 618 
to optimize prognostic scoring systems in CMML.117-120 619 
 620 
Flow Cytometry in CMML: Standards and Limitations 621 
 622 
Flow cytometry studies are an essential diagnostic tool in patients with (suspected) 623 
classical CMML, pre-CMML conditions and special CMML variants.121-132 Therefore, 624 
our faculty is of the opinion that it is standard to perform multi-color flow cytometry 625 
(MFC) in the PB and BM in all cases with suspected or known CMML or a suspected 626 
pre-CMML condition. MFC studies are helpful to confirm the monocyte and blast cell 627 
counts in these patients and to exclude AML. In addition, MFC is useful to confirm the 628 
 26 
presence of distinct monocyte populations. Monocytes are defined as CD14+ cells in 629 
these analyses. Based on expression of CD14 and CD16, monocytes are further 630 
divided into classical (MO1) monocytes (CD14bright/CD16−), intermediate (MO2) 631 
monocytes (CD14bright/CD16+) and non-classical (MO3) monocytes (CD14dim/CD16+) 632 
(Table 7).127,128,132 Compared to age-matched healthy donors133 and patients with 633 
reactive monocytosis, but also myeloid neoplasms other than CMML (even MDS), the 634 
percentages of MO1 monocytes in the peripheral blood are higher and the percentage 635 
of MO3 monocytes is lower in patients with CMML.127,131,132 When the absolute 636 
monocyte count is increased in the PB, a cutoff value of >94% MO1 monocytes, based 637 
on their immunophenotype, can identify CMML with a sensitivity of >90% and a 638 
specificity of >95%.127,129,131 Moreover, during successful therapy, the distribution of 639 
MO1, MO2, and MO3 monocytes changes back to near normal or normal.128 640 
Therefore, our faculty recommends that the percentages of MO1 monocytes are 641 
quantified in the peripheral blood by MFC in all cases with suspected or known 642 
CMML at diagnosis and during follow-up. 643 
In many cases with CMML, neoplastic monocytes aberrantly display CD2, CD5, 644 
CD10, CD23, and/or CD56.121-124 Of all aberrantly expressed surface markers, CD56 is 645 
most commonly detected on CMML monocytes.121-124 CD5 is only (very) weakly 646 
expressed on neoplastic monocytes in most cases with CMML. The most frequently 647 
underexpressed antigens may be CD14 and CD15. Overall, however, the use of 648 
decreased expression of these markers as a diagnostic test in CMML is limited by a 649 
relatively low sensitivity. An abnormal immunophenotype of monocytes is also seen in 650 
other myeloid neoplasms, including MDS. On the other hand, phenotypically aberrant 651 
monocytes (as described above) are typically neoplastic cells (unless the patient has 652 
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been treated with growth factors). Therefore, our faculty recommends that MFC 653 
studies in patients with (suspected) CMML employ antibodies directed against 654 
aberrantly expressed surface markers, including CD2 and CD56. Additionally several 655 
surface markers are ´under-expressed´ on CMML monocytes when comparing to 656 
normal blood monocytes. These antigens include, among others, CD13, CD14, CD33, 657 
CD36, CD38, CD45, and CD64.121-124,129,131  658 
Other cell types may also express aberrant markers by MFC in CMML. For example, 659 
myeloid progenitor cells may express CD56 in CMML and often exhibit the same 660 
phenotypic abnormalities like in MDS; this holds also true for neutrophils and 661 
erythroid cells (Supplementary Table S8). Other cell types that may show aberrant 662 
phenotypes are dentritic cells and mast cells. Especially mast cells are of considerable 663 
importance as these cells may be indicative of the presence of a concomitant 664 
mastocytosis (SM-CMML). In these cases, mast cells almost invariably express CD25 665 
in MFC analyses (Supplementary Table S8).134 Overall, our faculty is of the opinion 666 
that MFC studies should be performed on monocyte subsets, myeloid progenitors, 667 
neutrophils, erythroid cells and mast cells. An overview of immunophenotypic 668 
aberrancies detectable in CMML is shown in Supplementary Table S8. 669 
 670 
Differential Diagnoses of CMML: Reactive and Clonal Mimickers 671 
 672 
A number of conditions can mimick CMML and have to be taken into account when 673 
patients with unexplained monocytosis are evaluated. Reactive disorders mimicking 674 
CMML include, among others, certain chronic bacterial infections (examples: 675 
tuberculosis or subacute endomyocarditis), fungal infections, chronic auto-immune 676 
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processes and non-hematologic neoplasms. There are also hematologic malignancies 677 
which may present as a CMML-like disease. For example, Ph+ CML is usually 678 
presenting with (absolute) monocytosis and can also show signs of dysplasia. 679 
Particularly high monocyte counts are recorded in CML cases expressing BCR-680 
ABL1p190. When cryptic variants of BCR-ABL1 are expressed by leukemic cells, it can 681 
be difficult to exclude CMML. Myeloid neoplasms (MDS or MPN) in progression 682 
and myelomonocytic or monocytic AML may also resemble CMML. The reactive and 683 
clonal mimickers of CMML are listed in Supplementary Table S9. 684 
 685 
Scoring Systems in CMML: Recommended Standards 686 
 687 
Although several prognostic variables have been identified in CMML regarding 688 
survival and AML evolution, accurate prediction of the clinical course and survival 689 
remains a clinical challenge. A first step in prognostication is grading into CMML-0, 690 
CMML-1 and CMML-2. To delineate the prognosis in CMML more accurately, a 691 
number of scoring systems have been developed in the past.29,117-121,135-138 Until 2012, 692 
the international prognostic scoring system (IPSS) served as a golden standard of 693 
prognostication in MDS and (dysplastic) CMML.135 694 
However, a number of more specific scoring systemic taking CMML-related features 695 
into account have also been proposed.117-120,136-138 During the past few years, 696 
researchers have successfully started to integrate cytogenetic and molecular variables 697 
into these scoring models.117-121 Our faculty concludes that these novel approaches 698 
should be followed and developed into clinical application. 699 
 700 
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Management Strategies and Therapeutic Options in CMML 701 
 702 
Several new treatment strategies for CMML have been developed during the past 15 703 
years. A detailed description of therapeutic options is beyond the scope of this article. 704 
The reader is referred to a series of excellent published review articles.139-146 A 705 
disappointing fact is that all drug therapies are still non-curative. The only curative 706 
therapy in CMML remains allo-HSCT.147,148 For most young and eligible patients with 707 
acceptable transplant-related risk, allo-HSCT is therefore recommended. All other 708 
forms of treatment are cytoreductive, experimental or palliative in nature. Some of 709 
these drugs, like the hypomethylating agents (5-azacytidine, decitabine) may induce 710 
long-term disease control in a subset of patients with classical CMML.139-145 In 711 
general, cytoreductive and palliative drugs should be applied according to available 712 
recommendations provided by major societies.145,148 Similarly, treatment response 713 
assessment should be performed in line with available (accepted) guidelines.146,150 714 
Specific therapy may work in those patients who suffer from a special variant of 715 
CMML. For example, in CMML patients with a transforming PDGFRA/B mutation, 716 
treatment with imatinib or other similar TKI usually induces major responses or even 717 
long-lasting remissions.47-49,151 In patients with SM-CMML, midostaurin may result in 718 
disease control, especially when the CMML-portion of the disease exhibits KIT 719 
D816V. However, in many cases, relapses occur. Treatment options in CMML and its 720 
variants are summarized in Supplementary Table S10. 721 
 722 
Concluding Remarks and Future Perspectives 723 
 724 
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CMML is a unique and rare hematopoietic neoplasm with a complex biology and 725 
pathology. In the past 10 years, several different pre-CMML conditions and sub-726 
variants of CMML have been defined. In the current article, we propose minimal 727 
diagnostic criteria for classical CMML and for special CMML variants. These criteria 728 
should help in the diagnosis of pre-CMML conditions, classical CMML, special 729 
CMML variants, and conditions that mimick CMML. In addition, we propose 730 
standards and tools for the diagnosis, prognostication and management of CMML. 731 
Contemporary assays define all major histopathologic, molecular, cytogenetic and 732 
flow cytometry-based features of neoplastic cells, and thereby cover all CMML 733 
variants, including oligomonocytic CMML and CMML associated with certain drivers 734 
or a concomitant myeloid neoplasm, such as mastocytosis. Different aberration 735 
profiles may also be found, resulting in a quite heterogeneous clinical picture and a 736 
variable clinical course. Although the course is often unpredictable, initial grading and 737 
consecutive application of CMML-directed prognostic scores are standard tools that 738 
support the prognostication of patients with CMML concerning survival and AML 739 
evolution. The application of criteria, tools and standards proposed herein should assist 740 
in the diagnosis, prognostication and management of patients with CMML. 741 
 742 
 743 
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Tables 1536 
Table 1 1537 
 1538 
Minimal Diagnostic Criteria of Classical CMML* 1539 
----------------------------------------------------------------------------------------------------------------- 1540 
A. Prerequisite Criteria (all must be fulfilled) 1541 
 1542 
- Persistent (3 months) peripheral blood monocytosis ≥1x109/L and (plus)  1543 
  relative monocytosis of ≥10% of circulating peripheral blood leukoyctes 1544 
 1545 
- Exclusion of BCR-ABL1+ leukemia, classical MPN and all other bone marrow  1546 
  neoplasms that could serve as a primary source of chronic persistent monocytosis 1547 
 1548 
- Blast cell count of <20% in peripheral blood and bone marrow smears and (plus) exclusion  1549 
  of all other histopathological, morphologic, molecular and cytogenetic features that 1550 
  count as evidence for the presence of acute myeloid leukemie (AML)** 1551 
 1552 
B. Morphologic criterion = Dysplasia 1553 
 1554 
- Dysplasia in at least 10% of all cells in one of the following lineages 1555 
   in the bone marrow smear: erythroid; neutrophilic; megakaryocytic  1556 
 1557 
C. Co-Criteria (for patients fulfilling A but not B, and otherwise show typical 1558 
    clinical features of CMML such as splenomegaly)  1559 
 1560 
- Typical chromosome abnormalities by conventional karyotyping or FISH*** 1561 
 1562 
- Abnormal findings in histologic and/or immunohistochemical studies of bone  marrow 1563 
  biopsy sections supporting the diagnosis of CMML****  1564 
 1565 
- Abnormal immunophenotype of bone marrow and blood cells by flow cytometry, 1566 
  with multiple CMML-associated phenotypic aberrancies indicating the presence of an  1567 
  abnormal/dysplastic population of monocytic and other myeloid cells*****       1568 
 1569 
- Evidence of a clonal population of myeloid cells determined by molecular 1570 
  (sequencing) studies revealing CMML-related mutations******  1571 
-----------------------------------------------------------------------------------------------------------------  1572 
*The diagnosis of classical CMML can be established when all prerequisite criteria (´A´)  1573 
  and either morphologic dysplasia (´B´) or one or more of the co-criteria (´C´) are fulfilled.  1574 
**Examples: Auer rods, overt AML by histology and immunohistochemistry; presence 1575 
    of AML-specific diagnostic cytogenetic and/or molecular markers (e.g., inv16). 1576 
***Typical cytogenetic abnormalities found in CMML (Supplementary Table S6).   1577 
****Leukemic infiltration of CD14+ monocytes and exclusion of AML. 1578 
*****Utilizing a cutoff value of >94% MO1 monocytes, phenotyping can identify CMML 1579 
cases with a sensitivity of >90% and a specificity of >95%, and the decrease in MO3 1580 
monocytes is even as diagnostic as the increase in circulating MO1 cells.122,124,126 1581 
******Genes that are often mutated in the CMML/MDS context include, among other, TET2,  1582 
SRSF2, ASXL1 and SETBP1. Minimal allele burden proposed to count as co-criterion: ≥10%. 1583 
Abbreviations: CMML, chronic myelomonocytic leukemia; MPN, myeloproliferative 1584 
neoplasm(s); MDS, myelodysplastic syndrome(s); FISH, fluorescence in situ hybridization. 1585 
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 1587 
Table 2 1588 
 1589 
Overview of Special Variants of CMML 1590 
----------------------------------------------------------------------------------------------------------------- 1591 
               Key diagnostic features that discriminate  1592 
Special variant            the variant from classical CMML  1593 
----------------------------------------------------------------------------------------------------------------- 1594 
Oligomonocytic CMML        Absolute PB monocyte count <1x109/L 1595 
 1596 
Systemic mastocytosis (SM) with     WHO criteria for SM fulfilled; in most patients 1597 
concomitant CMML = SM-CMML    CMML monocytes exhibit KIT D816V 1598 
 1599 
CMML with a concomitant myeloid    WHO criteria for a classical MPN, such  1600 
neoplasm* expressing a classical MPN-   as CML**, PMF, or a myeloid neoplasm with 1601 
driver, such as JAK2 V617F, BCR-ABL1  rearranged PDGFRA/B are fulfilled in addition  1602 
or rearranged PDGFRA/B*** or FGFR1. to the criteria of CMML. 1603 
 1604 
CMML with expression of a molecular   Molecular drivers of classical MPN, such as  1605 
MPN-driver – examples:          JAK2 V617F**** or rearranged PDGFRA/B***   1606 
CMML with JAK2 V617F or       are found but diagnostic criteria for such  1607 
CMML with a rearranged PDGFRA/B or  classical MPN are not fulfilled (only criteria for  1608 
CMML with rearranged FGFR1.     CMML are met) 1609 
 1610 
CMML with a concomitant lymphoid/     WHO criteria for a lymphoid neoplasm are 1611 
lymphoproliferative neoplasm      fulfilled  1612 
----------------------------------------------------------------------------------------------------------------- 1613 
*These conditions have to be separated from MPN with concomitant monocytosis that does 1614 
not fulfil the diagnostic criteria of CMML.  1615 
**Unlike in SM-CMML where monocytes display KIT D816V or CMML with rearranged   1616 
PDGFRA, the CMML monocytes must not express BCR-ABL1 in patients with CML plus 1617 
CMML. 1618 
***Several different translocations and fusion genes involving PDGFRA or PDGFRB may be 1619 
dected, such as the t(5;12) associated with the TEL-PDGFRB fusion gene. 1620 
****JAK2 V617F itself counts as a feature of MPN; therefore, detection of JAK2 V617F can 1621 
confirm the diagnosis CMML (as MPN/MDS overlap disease) when other signs of 1622 
myeloproliferation are absent (e.g., no splenomegaly and no leukocytosis).  1623 
Abbreviations: CMML, chronic myelomonocytic leukemia; PB, peripheral blood; WHO, 1624 
World health organization; CML chronic myeloid leukemia. 1625 
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 1627 
Table 3 1628 
 1629 
Proposed Minimal Diagnostic Criteria for Oligomonocytic CMML* 1630 
----------------------------------------------------------------------------------------------------------------- 1631 
A. Prerequisite Criteria (all must be fulfilled) 1632 
 1633 
- Persistent (3 months) peripheral blood monocytosis 0.5-0.9x109/L and (plus)  1634 
  relative monocytosis of ≥10% of circulating peripheral blood leukoyctes 1635 
 1636 
- Exclusion of BCR-ABL1+ leukemia, classical MPN and all other bone marrow  1637 
  neoplasms that could serve as a primary source of chronic persistent monocytosis 1638 
 1639 
- Blast cell count <20% in peripheral blood and bone marrow smears and (plus) exclusion  1640 
  of all other histopathological, morphologic, molecular and cytogenetic features that 1641 
  count as evidence for the presence of acute myeloid leukemie (AML)** 1642 
 1643 
B. Morphologic criterion = Dysplasia 1644 
 1645 
- Dysplasia in at least 10% of all cells in one of the following lineages 1646 
   in the bone marrow smear: erythroid; neutrophilic; megakaryocytic  1647 
 1648 
C. Co-Criteria (for patients fulfilling A but not B, and otherwise show typical 1649 
    clinical features of CMML such as splenomegaly)  1650 
 1651 
- Typical chromosome abnormalities by conventional karyotyping or FISH*** 1652 
 1653 
- Abnormal findings in histologic and/or immunohistochemical studies of bone  marrow 1654 
  biopsy sections supporting the diagnosis of CMML****  1655 
 1656 
- Abnormal immunophenotype of bone marrow and blood cells by flow cytometry,   1657 
  with multiple CMML-associated phenotypic aberrancies indicating the presence of an  1658 
  abnormal/dysplastic population of monocytic (and other myeloid) cells*****       1659 
 1660 
- Evidence of a clonal population of myeloid cells determined by molecular 1661 
  (sequencing) studies revealing CMML-related mutations******  1662 
-----------------------------------------------------------------------------------------------------------------  1663 
*The diagnosis of classical CMML can be established when all prerequisite criteria (´A´)  1664 
  and either morphologic dysplasia (´B´) or one or more of the co-criteria (´C´) are fulfilled.  1665 
**Examples: Auer rods, overt AML by histology and immunohistochemistry; presence 1666 
    of AML-specific diagnostic cytogenetic and/or molecular markers (e.g., inv16). 1667 
***Typical cytogenetic abnormalities found in CMML (Supplementary Table S6).   1668 
****Leukemic infiltration of CD14+ monocytes and exclusion of AML. 1669 
*****Utilizing a cutoff value of >94% MO1 monocytes, phenotyping can identify CMML 1670 
cases with a sensitivity of >90% and a specificity of >95%, and the decrease in MO3 1671 
monocytes is even as diagnostic as the increase in circulating MO1 cells.122,124,126 1672 
******Genes that are often mutated in the CMML/MDS context include, among other, TET2,  1673 
SRSF2, ASXL1 and SETBP1. Minimal allele burden proposed to count as co-criterion: ≥10%. 1674 
Abbreviations: CMML, chronic myelomonocytic leukemia; MPN, myeloproliferative 1675 
neoplasm(s); MDS, myelodysplastic syndrome(s); FISH, fluorescence in situ hybridization. 1676 
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 1679 
Table 4 1680 
 1681 
Overview of Non-Clonal and Clonal Conditions that may precede CMML 1682 
----------------------------------------------------------------------------------------------------------------- 1683 
         Pre-CMML conditions and comparison to classical CMML 1684 
     ----------------------------------------------------------------------------------------------- 1685 
Feature      IMUS ICUS  CCUS  CHIP/CHOP  CMUS O-CMML CMML 1686 
----------------------------------------------------------------------------------------------------------------- 1687 
Absolute  1688 
Monocytosis    +   +/-  +/-  +/-    +    +   +   1689 
(≥0.5x109/L)   1690 
 1691 
Substantial 1692 
Monocytosis    +/-  -   -   -     +/-   -   +   1693 
(≥1x109/L)     1694 
 1695 
Relative Monocytosis +   -   -   -     +    +   + 1696 
(>10% of leukocytes) 1697 
 1698 
Dysplasia*     -   -   -   -     -    +   + 1699 
 1700 
Cytopenia(s)**   -   +   +   -     -    +/-  +/- 1701 
 1702 
BM blasts      <5%  <5%  <5%  <5%    <5%   <20% <20% 1703 
 1704 
Flow abnormalities  -   -   +/-  +/-    -    ++  ++ 1705 
 1706 
Cytogenetic  1707 
Abnormalit(y)ies   -***  -***  +/-  +/-    -***   ++  ++ 1708 
 1709 
Molecular  1710 
Aberration/s****   -    -   +   +     +****  ++  ++ 1711 
----------------------------------------------------------------------------------------------------------------- 1712 
*At least 10% of all cells in a given lineage (erythroid, neutrophil, or platelet) are dysplastic. 1713 
**Persistent cytopenia(s) recorded over a time-period of at least 4 months. 1714 
***In a subset of cases, a small-sized clone is detectable by FISH.  1715 
****A molecular aberration is defined by CMML/MDS-related mutations and an allele 1716 
burden of ≥2%. The working definition for pre-CMML conditions is also ≥2% allele burden, 1717 
whereas the minimal allele burden to count as a co-criterion of CMML is 10%. In most 1718 
patients with overt CMML, multiple gene mutations/aberrations are found.  1719 
Abbreviations: CMML, chronic myelomonocytic leukemia; IMUS, idiopathic monocytosis of 1720 
unknown (undetermined) significance; ICUS, idiopathic cytopenia of undetermined 1721 
significance; CCUS, clonal cytopenia of undetermined significance; CHIP, clonal 1722 
hematopiesis of indeterminate potential; CCUS, clonal cytopenia of undetermined 1723 
significance; CMUS, clonal monocytosis of unknown (undetermined) significance; O-1724 
CMML, oligomonocytic CMML; MDS, myelodysplastic syndrome; BM, bone marrow; 1725 
FISH, fluorescence in situ hybridization.  1726 
****Here a CHIP-like mutation is detected – if more than one CHIP-like mutations are found 1727 
the question is whether the final diagnoses changes to O-CMML. 1728 
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 1730 
Table 5 1731 
 1732 
Classification of Blast Cells and Monocytes in Patients with CMML 1733 
----------------------------------------------------------------------------------------------------------------- 1734 
                              Size relative to 1735 
Cell Type      Nuclear shape  Chromatin    Cytoplasm    mature monocytes 1736 
----------------------------------------------------------------------------------------------------------------- 1737 
Blast cells: 1738 
 1739 
Myeloblast     Round/oval   Fine with   Basophilic,    Smaller  1740 
               nucleoli     rare or no     1741 
                     granules    1742 
 1743 
Monoblast      Round/oval   Delicate /    Basophilic,    Large 1744 
               lace-like,           rare azurophilic  (20-30 µM) 1745 
               nucleoli    granules 1746 
 1747 
Promonocyte     Convoluted/   Delicate /   Variably basophilic,  Large  1748 
        indented*     lace-like,   variable azurophilic 1749 
               nucleoli     granules 1750 
Monocytes: 1751 
 1752 
Abnormal/immature   Convoluted/      More condensed, Intermediate    Smaller 1753 
monocyte     indented    rare nucleoli  basophilic** 1754 
 1755 
Mature monocyte   Lobulated/    Condensed,  Grey or pinkish      =  1756 
         indented     no nucleoli   with occasional  1757 
                     azuroophilic  1758 
                     granules 1759 
                     and vacuoles  1760 
----------------------------------------------------------------------------------------------------------------- 1761 
*The most important delineating feature discriminating promonocytes from monoblasts. 1762 
**Less basophilic than promonocytes and more basophilic than mature monocytes.  1763 
 1764 
 1765 
 1766 
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Table 6 1768 
 1769 
Commonly Mutated Genes Detectable in Patients with Classical CMML 1770 
-------------------------------------------------------------------------------------------------------- 1771 
                   Relative 1772 
Gene Name      Gene Class      Frequency   Clinical    1773 
Abbreviation      and function      in CMML   Impact 1774 
-------------------------------------------------------------------------------------------------------- 1775 
ASXL1      Epigenetic regulation   40%*    poor prognosis** 1776 
         Histone modification         CHIP/ARCH*** 1777 
EZH2        Epigenetic regulation   5%   1778 
         Histone modification 1779 
TET2        Epigenetic regulation   60%*    CHIP/ARCH*** 1780 
         DNA methylation 1781 
DNMT3A      Epigenetic regulation   5%      poor prognosis** 1782 
         DNA methylation            CHIP/ARCH*** 1783 
IDH1      Epigenetic regulation   1%     drug target 1784 
IDH2        Epigenetic regulation   5-10%    drug target 1785 
CBL       Signaling         15%      RAS pathway 1786 
NRAS       Signaling       15%     poor prognosis** 1787 
                         RAS pathway 1788 
KRAS       Signaling        10%     RAS pathway 1789 
PTPN11       Signaling       5%     RAS pathway 1790 
FLT3      Signaling        <5%     AML-related 1791 
                         drug target 1792 
SRSF2       Pre‐mRNA splicing   50%*      1793 
SF3B1       Pre‐mRNA splicing   5-10%   1794 
U2AF1      Pre‐mRNA splicing   5-10%   1795 
ZRSR2      Pre‐mRNA splicing   5%   1796 
RUNX1      Gene transcription    15%     poor prognosis**  1797 
                         AML-related  1798 
SETBP1       Gene transcription    15%     poor prognosis* * 1799 
TP53        DNA damage     1%     poor prognosis* * 1800 
PHF6        Chromatin adaptor    5%      1801 
-------------------------------------------------------------------------------------------------------- 1802 
*These mutations can be regarded as CMML-related mutations, but only SRSF2 1803 
mutations do not, in addition, also count as classical CHIP/ARCH mutations. 1804 
**Mutations in these genes are independent adverse prognostic factors concerning 1805 
survival in CMML. ***These genes are frequently detected in individuals with clonal 1806 
hematopoiesis of interminate potential (CHIP) also known as age-related clonal 1807 
hematopoiesis (ARCH). Therefore, the diagnostic impact of these mutations may be 1808 
regared as somehow lower compared to other (CMML-related and other) mutations. 1809 
Abbreviations: CMML, chronic myelomonocytic leukemia; AML, acute myeloid 1810 
leukemia.  1811 
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 1817 
Table 7 1818 
 1819 
Phenotypic Classification of Monocytes and Distribution of Monocyte-Subsets in 1820 
CMML and Controls* 1821 
-------------------------------------------------------------------------------------------------------- 1822 
                   Typical Relative Frequency in* 1823 
Monocyte      Defining   -------------------------------------------------------1824 
-Subset       Phenotype       CMML  MDS or MPN   Reactive BM 1825 
-------------------------------------------------------------------------------------------------------- 1826 
Classical (MO1)   CD14bright/CD16−  ≥94%   70-97%    <94% 1827 
  1828 
Intermediate (MO2)   CD14bright/CD16+  <20%  5-20%     5-15% 1829 
 1830 
Non-classical (MO3)  CD14dim/CD16+   <5%   5-10%    5-20% 1831 
-------------------------------------------------------------------------------------------------------- 1832 
*Data refer to published results presented in references #118 through #123. 1833 
Abbreviations: CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic 1834 
syndrome; MPN, myeloproliferative neoplasm; BM, bone marrow. 1835 
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